Children's Hospital Los Angeles and Keck School of Medicine of USC, Center for Endocrinology, Diabetes and Metabolism, Los Angeles, CA, United States.
Cancer Research Center on Health Equity, Cedars-Sinai Medical Center, West Hollywood, CA, United States.
Obes Res Clin Pract. 2021 Sep-Oct;15(5):431-438. doi: 10.1016/j.orcp.2021.08.006. Epub 2021 Sep 2.
This scoping review provides a timely synthesis of the use of continuous glucose monitoring in obesity research with considerations to adherence to continuous glucose monitor devices and metrics most frequently reported.
This scoping review was conducted adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist. Eligible studies (n = 31) evaluated continuous glucose monitor use in research on participants, of all ages, with overweight or obesity.
Reviewed studies varied in duration from one to 84 days (mean: 8.74 d, SD 15.2, range 1-84 d) with 889 participants total (range: 11-118 participants). Across all studies, the mean percent continuous glucose monitor wear time (actual/intended wear time in days) was 92% (numerator - mean: 266.1 d, SD: 452, range: 9-1596 d/denominator - mean: 271.6 d, SD: 451.5, range: 9-1596 d). Continuous glucose monitoring was utilized to provide biofeedback (n = 2, 6%), monitor dietary adherence (n = 2, 6%), and assess glycemic variability (n = 29, 93%). The most common variability metrics reported were standard deviation (n = 19, 62%), area under the curve (n = 12, 39%), and glycemic range (n = 12, 39%).
Available evidence suggests that continuous glucose monitoring is a well-tolerated and versatile tool for obesity research in pediatric and adult patients. Future investigation is needed to substantiate the feasibility and utility of continuous glucose monitors in obesity research and maximize comparability across studies.
本范围综述及时综合了肥胖研究中连续血糖监测的应用情况,并考虑了连续血糖监测设备的依从性和最常报告的指标。
本范围综述按照系统评价和荟萃分析扩展的首选报告项目(PRISMA-ScR)清单进行。合格研究(n=31)评估了超重或肥胖参与者的连续血糖监测器使用情况。
综述研究的持续时间从一天到 84 天不等(平均值:8.74 天,标准差 15.2,范围 1-84 天),共有 889 名参与者(范围:11-118 名参与者)。在所有研究中,连续血糖监测器佩戴时间的平均百分比(实际/预期佩戴时间,以天为单位)为 92%(分子-平均值:266.1 天,标准差:452,范围:9-1596 天/分母-平均值:271.6 天,标准差:451.5,范围:9-1596 天)。连续血糖监测用于提供生物反馈(n=2,6%)、监测饮食依从性(n=2,6%)和评估血糖变异性(n=29,93%)。报告的最常见变异性指标是标准差(n=19,62%)、曲线下面积(n=12,39%)和血糖范围(n=12,39%)。
现有证据表明,连续血糖监测在儿科和成年肥胖患者的研究中是一种耐受良好且多功能的工具。需要进一步研究证实连续血糖监测在肥胖研究中的可行性和实用性,并最大限度地提高研究之间的可比性。